Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Researchers have discovered a new mechanism that is used by a male sex hormone essential for muscle and bone function. The ...

Short chains of amino acids can form drug delivery nanoparticles and boost the properties of potential medicines ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

As well as being essential in the precise packaging of DNA into the space of the nucleus, histone proteins are also the site ...

New research has investigated the mechanism by which bivalency functions to poise genes for expression during cell differentiation, providing insight into a long-standing paradigm in the regulation of ...

The European Commission has become the first regulator worldwide to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Molecular dynamics is a method that uses Newton ... the process of oligomer formation of the transmembrane pore structure has not yet been elucidated. Here, the authors examine and compare ...

The ACS Scholars Program awards renewable scholarships to undergraduate students from historically underrepresented groups in the chemical sciences, majoring in chemistry-related disciplines, and ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent—including agreements with payers and pharmacy benefit managers that ...